This site is intended for health professionals only
Wednesday 12 December 2018
Share |

Topic: blood cancer

July 2, 2018
The CHMP has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.

The Committee for Medicinal Products for Human Use (CHMP) has given a positive opinion recommending Novartis’s Kymriah (tisagenlecleucel) to treat two aggressive blood cancers.
 
The CHMP, which is part of the European Medicines Agency (EMA), gave a positive opinion on using tisagenlecleucel to treat B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-stem cell transplant or in second or later relapse in patients up to 25 years of age.
 

May 10, 2018
Blood cancer drugs brentuximab, vedotin, midostaurin will now be available on the NHS giving hundreds of individuals more therapy choices

The National Institute for Health and Care Excellence (NICE) has recommended three blood cancer drugs, brentuximab vedotin, midostaurin and arsenic trioxide be made available on the NHS.

 

Two of the therapies, midostaurin, also known as the Novartis drug Rydapt, and arsenic trioxide, Teva’s Trisenox, are recommended for adults with certain types of leukaemia.

 

May 3, 2018
Study finds the addition of this medicine to lenalidomide and dexamethasone (KRd) can extend the life of people with incurable blood cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a label variation for KYPROLIS® (carfilzomib) to include the final overall survival data, following a recent Phase III trial.

 

KYPROLIS® is the first and only relapsed or refractory multiple myeloma treatment to demonstrate overall survival (OS) in two Phase III studies, Amgen, the American multi-national biopharmaceutical company, has announced [April 30].

 

April 12, 2018
Gene discovery could lead to future individualised therapy in myeloma, researchers find

Researchers have increased the understanding of the complex genetics behind an incurable blood cancer.

 

The Institute of Cancer Research, London, has conducted a study which has revealed 40 genes involved in the development of myeloma, enhancing the knowledge about the complex genetics associated with this condition.

 

April 20, 2009
Bone-strengthening drugs commonly used to prevent osteoporosis could help protect against a type of blood cancer

teaser

February 25, 2008
The US Food and Drug Administration (FDA) has approved a phase III clinical trial for a new cancer drug, manufacturer Kiadis Pharma said

teaser

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?

Close

Respect for nurses: Sign up to our e-petition TODAY

The Nursing in Practice Respect campaign is now live! Over the coming months, we're set to highlight the vital contribution and efforts of primary care and community care nurses throughout the UK.

As part of our campaign, Nursing in Practice is looking to call on parliament to set up a debate to celebrate the vital work that you do.


GET INVOLVED: SIGN OUR E-PETITION

Close

Calling all primary care nurses! 'Like' our Nursing in Practice Facebook page to enter our free draw to win a £25 M&S voucher




http://www.facebook.com/NursinginPracticeMagazine